Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

Around, 30–40% of HER2-positive breast cancers do not show substantial clinical benefit from the targeted therapy and, thus, the mechanisms underlying resistance remain partially unknown. Interestingly, ERBB2 is frequently co-amplified and co-expressed with neighbour genes that may play a relevant r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hergueta-Redondo, Marta, Sarrio, David, Molina-Crespo, Ángela, Vicario, Rocío, Bernadó-Morales, Cristina, Martínez, Lidia, Rojo-Sebastián, Alejandro, Serra-Musach, Jordi, Mota, Alba, Martínez-Ramírez, Ángel, Castilla, Maria Ángeles, González-Martin, Antonio, Pernas, Sonia, Cano, Amparo, Cortes, Javier, Nuciforo, Paolo G., Peg, Vicente, Palacios, José, Pujana, Miguel Ángel, Arribas, Joaquín, Moreno-Bueno, Gema
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302915/
https://www.ncbi.nlm.nih.gov/pubmed/27462779
http://dx.doi.org/10.18632/oncotarget.10787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302915/
https://www.ncbi.nlm.nih.gov/pubmed/27462779
http://dx.doi.org/10.18632/oncotarget.10787

Ejemplares similares